Maldives Bans E-Cigarette Imports and Sales, Imposes Heavy Fines

Nov.08.2024
Maldives Bans E-Cigarette Imports and Sales, Imposes Heavy Fines
Maldives Parliament passed amendments to the Tobacco Control Act, banning e-cigarettes and raising minimum age for tobacco products to 21.

According to The Edition on November 7th, the Maldives Parliament's Social Affairs Committee has approved amendments to the Tobacco Control Act, which includes a complete ban on the sale of e-cigarettes and raising the minimum age to purchase tobacco products to 21 years old.


According to Member of Parliament Ahmed Aifan, who submitted the draft to the Parliament, starting November 15, the import of e-cigarettes will be banned, followed by a complete ban on the use, distribution, and sale of e-cigarettes starting December 15.


According to the amendment, violations of the law will face harsh penalties. Importing e-cigarettes or related products after the ban comes into effect will result in a fine of 50,000 Maldivian Rufiyaa ($3,200), with an additional fine of 10,000 Rufiyaa ($650) for each e-cigarette or vaporizer imported.


Illegal sales of these products will result in a fine of 20,000 Maldivian Rufiyaa (1300 USD), with an additional fine of 10,000 Rufiyaa (650 USD) for each item sold. Distributing these products for free will also incur a fine of 10,000 Maldivian Rufiyaa (650 USD).


If these products are sold to minors, the fine will increase to 50,000 Maldivian Rufiyaa (3,200 US dollars).


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Reuters: FDA relaxes requirements for nicotine pouch pilot program, cancels special research on some products
Reuters: FDA relaxes requirements for nicotine pouch pilot program, cancels special research on some products
US FDA meeting minutes: Under Trump, a new pilot eases nicotine pouch rules—cuts product-specific research (uses generic data), shortens reviews, boosts communication. It’s the FDA’s first clear softer stance on smoking alternatives. The pilot may benefit Philip Morris (Zyn), Altria (On!), BAT (Velo) but sparks debate: FDA says pouches are low-risk (no youth surge), while ex-officials/academics cite missing research (hurts health checks, risks hidden youth use). Firms note costly research remain
Sep.19 by 2FIRSTS.ai
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly: Nearly 44,500 Students Used Cigarettes or Vapes in 2024
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly: Nearly 44,500 Students Used Cigarettes or Vapes in 2024
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly Ahmad reported that 44,441 students—44,211 secondary and 230 primary—were identified as users of smoking products in 2024 through the Oral Health Without Smoking Practices Programme. The Health Ministry cited ongoing cessation support via 857 clinics and the JomQuit digital platform, with 4,916 adults successfully quitting after setting a quit date last year.
Sep.10
BAT Fiji invests $1 million to upgrade tobacco curing barn, achieving annual savings of $200,000
BAT Fiji invests $1 million to upgrade tobacco curing barn, achieving annual savings of $200,000
British American Tobacco (BAT) Fiji has completed a $1 million upgrade to a curing barn in Votualevu, Nadi, shifting from diesel to a more sustainable fuel source. The project—part of BAT’s ESG programme—targets an annual reduction of 428 tonnes of carbon emissions and up to $200,000 in yearly cost savings.
Sep.09
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
Juul’s San Francisco Headquarters May Be Sold as Debt Talks Advance
Juul’s San Francisco Headquarters May Be Sold as Debt Talks Advance
Real estate firm Affinius Capital is in talks to sell the loan tied to Juul’s San Francisco headquarters, with Madison Capital emerging as a potential buyer. If completed, the deal could lead to a change in ownership six years after Juul first acquired the building, signaling continued asset adjustments amid regulatory pressure.
Oct.23
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai